IL1A and epilepsy: Importantly, a systematic review of reports using anti-inflammatory therapeutics for treating patients with refractory epilepsy showed biological agents targeting the IL-1 pathway using receptor antagonists along with downstream targeting of IL-6, led to improved clinical outcomes (Costagliola et al., 2022).